A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Patnaik, A., Haluska, P., Tolcher, A. W., Erlichman, C., Papadopoulos, K. P., Lensing, J. L., Beeram, M., Molina, J. R., Rasco, D., Arcos, R. R., Kelly, C. S., Wijayawardana, S. R., Zhang, X., StancatLanguage:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-15-1718
Date:
November, 2015
File:
PDF, 553 KB
english, 2015